Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Leukemia | Review

Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials

Authors: Maha M. Salama, Nora M. Aborehab, Nihal M. El Mahdy, Ahmed Zayed, Shahira M. Ezzat

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Leukemia is a group of malignant disorders which affect the blood and blood-forming tissues in the bone marrow, lymphatic system, and spleen. Many types of leukemia exist; thus, their diagnosis and treatment are somewhat complicated. The use of conventional strategies for treatment such as chemotherapy and radiotherapy may develop many side effects and toxicity. Hence, modern research is concerned with the development of specific nano-formulations for targeted delivery of anti-leukemic drugs avoiding toxic effects on normal cells. Nanostructures can be applied not only in treatment but also in diagnosis. In this article, types of leukemia, its causes, diagnosis as well as conventional treatment of leukemia shall be reviewed. Then, the use of nanoparticles in diagnosis of leukemia and synthesis of nanocarriers for efficient delivery of anti-leukemia drugs being investigated in in vivo and clinical studies. Therefore, it may contribute to the discovery of novel and emerging nanoparticles for targeted treatment of leukemia with less side effects and toxicities.
Literature
1.
2.
Lockwood W. Leukemia: AML, CML, ALL and CLL. 2019.
3.
4.
Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. 2012;83(8):1041–8.PubMedCrossRef
5.
6.
7.
Shylasree TS, Bryant A, Athavale R. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst Rev. 2013;2013(2):cd00246.
8.
9.
Kubeček O, Paterová P, Novosadová M. Risk factors for infections, antibiotic therapy, and its impact on cancer therapy outcomes for patients with solid tumors. Life. 2021;11(12):1387.PubMedPubMedCentralCrossRef
10.
Banu H, et al. Doxorubicin loaded polymeric gold nanoparticles targeted to human folate receptor upon laser photothermal therapy potentiates chemotherapy in breast cancer cell lines. J Photochem Photobiol B. 2015;149:116–28.PubMedCrossRef
11.
Jurj A, et al. The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Dev Ther. 2017;11:2871.CrossRef
12.
Irimie AI, et al. Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics. Acta Odontol Scand. 2015;73(3):161–8.PubMedCrossRef
13.
Herbrink M, et al. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412–22.PubMedCrossRef
14.
Vlad C, et al. Evaluation of clinical, morphopathological and therapeutic prognostic factors in rectal cancer. Experience of a tertiary oncology center. J Buon. 2015;20(1):92–9.PubMed
15.
Wang Y, Chen L. Quantum dots, lighting up the research and development of nanomedicine. Nanomed Nanotechnol Biol Med. 2011;7(4):385–402.CrossRef
16.
17.
18.
Li J, et al. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. J Hematol Oncol. 2023;16(1):65.PubMedPubMedCentralCrossRef
19.
Wang R, et al. Advanced nanoparticles that can target therapy and reverse drug resistance may be the dawn of leukemia treatment: a bibliometrics study. Front Bioeng Biotechnol. 2022;10:1027868.PubMedPubMedCentralCrossRef
20.
21.
22.
23.
Eichhorst B, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33.PubMedCrossRef
24.
Hochhaus A, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41–51.PubMedCrossRef
25.
26.
Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16(11):684–701.PubMedCrossRef
27.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709.PubMedCrossRef
28.
Eden RE, Coviello JM. Chronic myelogenous leukemia. In: StatPearls. 2020: StatPearls Publishing.
29.
30.
Balakrishnan K, et al. Hide and seek: the game between chronic lymphocytic leukaemia cells and B cell receptor signalling inhibitors. EMJ. 2017;2(1):24–30.CrossRef
31.
Li XT, et al. Nanoparticle-delivered therapeutic agents targeting the tumor microenvironment for antitumor therapy. Discov Med. 2021;32(166):93–107.PubMed
32.
Hoellenriegel J, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012;26(7):1576–83.PubMedPubMedCentralCrossRef
33.
Friedman DR, et al. Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies. Leuk Lymphoma. 2014;55(5):1067–75.PubMedCrossRef
34.
35.
36.
37.
Tzoneva G, Ferrando AA. Recent advances on NOTCH signaling in T-ALL. In: Radtke F, editor. Notch regulation of the immune system. Berlin: Springer; 2012. p. 163–82.CrossRef
38.
39.
Zheng R, et al. Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia. Exp Hematol Oncol. 2020;9(1):1–9.CrossRef
40.
dos Santos Guimarães I, et al. Conventional cancer treatment. In: Rangel L, editor., et al., Cancer treatment-conventional and innovative approaches. London: Intech; 2013.
41.
42.
Stanczyk M, et al. Role of base-excision repair in the treatment of childhood acute lymphoblastic leukaemia with 6-mercaptopurine and high doses of methotrexate. Mutat Res. 2012;741(1–2):13–21.PubMedCrossRef
43.
Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8(1):24–36.PubMedCrossRef
44.
Im Kim K, et al. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. Eur J Cancer. 2013;49(2):403–10.CrossRef
45.
46.
47.
Fukushima T, et al. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol. 1993;57(2):121–30.PubMed
48.
Owattanapanich W, et al. Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18(12):814-821 e3.PubMedCrossRef
49.
Trifilio SM, et al. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res. 2012;36(4):394–6.PubMedCrossRef
50.
51.
Chen B, et al. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. J Exp Clin Cancer Res. 2018;37(1):1–11.PubMedPubMedCentralCrossRef
52.
Elagamy A, Elghoneimy LK, Arafa RK. Pyridine ring as an important scaffold in anticancer drugs. In: Singh P, editor. Recent developments in the synthesis and applications of pyridines. Amsterdam: Elsevier; 2023. p. 375–410.CrossRef
53.
Tura S, et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330(12):820–5.PubMedCrossRef
54.
Talpaz M, et al. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia. 2013;27(4):803–12.PubMedCrossRef
55.
56.
57.
58.
Tian H, et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15(1):132.PubMedPubMedCentralCrossRef
59.
Shen J, et al. Advances of nanoparticles for leukemia treatment. ACS Biomater Sci Eng. 2020;6(12):6478–89.PubMedCrossRef
60.
Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64–70.PubMedCrossRef
61.
Khademi R, et al. Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies. Nanoscale Adv. 2023;5(3):571–95.PubMedPubMedCentralCrossRef
62.
63.
64.
Krishnan V, Rajasekaran AK. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy. Clin Pharmacol Ther. 2014;95(2):168–78.PubMedCrossRef
65.
Soni G, Yadav KS. Applications of nanoparticles in treatment and diagnosis of leukemia. Mater Sci Eng C Mater Biol Appl. 2015;47:156–64.PubMedCrossRef
66.
67.
Tan J, et al. Aptamer-functionalized fluorescent silica nanoparticles for highly sensitive detection of leukemia cells. Nanoscale Res Lett. 2016;11(1):298.PubMedPubMedCentralCrossRef
68.
Khoshfetrat SM, Mehrgardi MA. Amplified detection of leukemia cancer cells using an aptamer-conjugated gold-coated magnetic nanoparticles on a nitrogen-doped graphene modified electrode. Bioelectrochemistry. 2017;114:24–32.PubMedCrossRef
69.
70.
MacLaughlin CM, et al. Surface-enhanced raman scattering dye-labeled Au nanoparticles for triplexed detection of leukemia and lymphoma cells and SERS flow cytometry. Langmuir. 2013;29(6):1908–19.PubMedCrossRef
71.
Haghighi FH, et al. Aptamer/magnetic nanoparticles decorated with fluorescent gold nanoclusters for selective detection and collection of human promyelocytic leukemia (HL-60) cells from a mixture. Nanotechnology. 2019;31(2): 025605.PubMedCrossRef
72.
Ensafi AA, et al. A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia. Biosens Bioelectron. 2016;77:409–15.PubMedCrossRef
73.
Mazloum-Ardakani M, et al. A new composite consisting of electrosynthesized conducting polymers, graphene sheets and biosynthesized gold nanoparticles for biosensing acute lymphoblastic leukemia. Bioelectrochemistry. 2018;121:38–45.PubMedCrossRef
74.
Bordbar MM, et al. A non-invasive tool for early detection of acute leukemia in children using a paper-based optoelectronic nose based on an array of metallic nanoparticles. Anal Chim Acta. 2021;1141:28–35.PubMedCrossRef
75.
76.
77.
78.
Simon AM, et al. Poly (D, L-lactic-co-glycolide) nanoparticles for the improved therapeutic efficacy of all-trans-retinoic acid: a study of acute myeloid leukemia (AML) cell differentiation in vitro. Med Chem. 2012;8(5):805–10.PubMedCrossRef
79.
Leung MHM, Shen AQ. Microfluidic assisted nanoprecipitation of PLGA nanoparticles for curcumin delivery to leukemia jurkat cells. Langmuir. 2018;34(13):3961–70.PubMedCrossRef
80.
Hasandoost L, et al. In vitro effect of imatinib mesylate loaded on polybutylcyanoacrylate nanoparticles on leukemia cell line K562. Artif Cells Nanomed Biotechnol. 2017;45(3):665–9.PubMedCrossRef
81.
82.
Palamà IE, et al. Coupled delivery of imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia. Biomater Sci. 2015;3(2):361–72.PubMedCrossRef
83.
Palamà IE, et al. mRNA delivery using non-viral PCL nanoparticles. Biomater Sci. 2015;3(1):144–51.PubMedCrossRef
84.
Valencia-Serna J, et al. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo. Eur J Pharm Biopharm. 2018;130:66–70.PubMedCrossRef
85.
Li Z, et al. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia. Int J Pharm. 2020;586: 119576.PubMedCrossRef
86.
87.
Petrushev B, et al. Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. Int J Nanomedicine. 2016;11:641–60.PubMedPubMedCentral
88.
Shahriari M, et al. Decoration of silver nanoparticles on multi-walled carbon nanotubes: Investigation of its anti-acute leukemia property against acute myeloid leukemia and acute T cell leukemia. Appl Organ Chem. 2020;34(4):e5476.CrossRef
89.
Felix DM, et al. Graphene quantum dots decorated with imatinib for leukemia treatment. J Drug Deliv Sci Technol. 2020;61: 102117.CrossRef
90.
91.
Anu K, et al. Biogenesis of selenium nanoparticles and their anti-leukemia activity. J King Saud Univ Sci. 2020;32(4):2520–6.CrossRef
92.
Hajinezhad MR, et al. Development of a new vesicular formulation for delivery of Ifosfamide: evidence from in vitro, in vivo, and in silico experiments. Arab J Chem. 2023;16(9): 105086.CrossRef
93.
94.
95.
Sun D, et al. Novel curcumin liposome modified with hyaluronan targeting CD44 plays an anti-leukemic role in acute myeloid leukemia in vitro and in vivo. ACS Appl Mater Interfaces. 2017;9(20):16857–68.PubMedCrossRef
96.
Zhang J, et al. Anti-leukemia activity of hyaluronic acid coated silver nanoparticles for selective targeting to leukemic cells. J Biomater Tissue Eng. 2018;8(6):906–10.CrossRef
97.
Durfee PN, et al. Mesoporous silica nanoparticle-supported lipid bilayers (protocells) for active targeting and delivery to individual leukemia cells. ACS Nano. 2016;10(9):8325–45.PubMedCrossRef
98.
Davis SM, et al. Leukemia inhibitory factor-loaded nanoparticles with enhanced cytokine metabolic stability and anti-inflammatory activity. Pharm Res. 2018;35(1):6.PubMedPubMedCentralCrossRef
99.
100.
Fan L, et al. Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches. Int J Pharm. 2020;579: 119179.CrossRef
101.
Lee D-J, et al. Systemic delivery of folate-PEG siRNA lipopolyplexes with enhanced intracellular stability for in vivo gene silencing in leukemia. Bioconjug Chem. 2017;28(9):2393–409.PubMedCrossRef
102.
Liu Y, et al. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy. Biomater Sci. 2018;6(6):1592–603.PubMedCrossRef
103.
Vinhas R, Fernandes AR, Baptista PV. Gold nanoparticles for BCR-ABL1 gene silencing: improving tyrosine kinase inhibitor efficacy in chronic myeloid leukemia. Mol Ther Nucleic Acids. 2017;7:408–16.PubMedPubMedCentralCrossRef
104.
Min QH, et al. Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365. Exp Cell Res. 2018;362(2):386–93.PubMedCrossRef
105.
Guo J, et al. Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy. Mol Pharm. 2017;14(3):940–52.PubMedCrossRef
106.
Dai Y, et al. Antiproliferative and apoptosis triggering potential of paclitaxel-based targeted-lipid nanoparticles with enhanced cellular internalization by transferrin receptors-a study in leukemia cells. Nanoscale Res Lett. 2018;13(1):271.PubMedPubMedCentralCrossRef
107.
Abdellatif AAH, et al. Fluorescent nanoparticles coated with a somatostatin analogue target blood monocyte for efficient leukaemia treatment. Pharm Res. 2020;37(11):217.PubMedCrossRef
108.
Niu F, et al. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy. Biomaterials. 2018;167:132–42.PubMedPubMedCentralCrossRef
109.
Wang Y, et al. Ultra-small Au/Pt NCs@GOX clusterzyme for enhancing cascade catalytic antibiofilm effect against F. nucleatum-induced periodontitis. Chem Eng J. 2023;466:143292.CrossRef
110.
Liu Y, et al. Biodegradable and cytocompatible hydrogel coating with antibacterial activity for the prevention of implant-associated infection. ACS Appl Mater Interfaces. 2023;15(9):11507–19.PubMedCrossRef
111.
Wang Y, et al. Surface-functionalized design of blood-contacting biomaterials for preventing coagulation and promoting hemostasis. Friction. 2023;11(8):1371–94.CrossRef
112.
113.
114.
Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71(3):555–64.PubMedCrossRef
115.
Garg R, et al. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Cancer Med. 2021;10(3):1128–40.PubMedCrossRef
116.
Metadata
Title
Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials
Authors
Maha M. Salama
Nora M. Aborehab
Nihal M. El Mahdy
Ahmed Zayed
Shahira M. Ezzat
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01539-z

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

A hypoxia- and lactate metabolism-related gene signature to predict prognosis of sepsis: discovery and validation in independent cohorts

Research

Ferrostatin-1 facilitated neurological functional rehabilitation of spinal cord injury mice by inhibiting ferroptosis

Review

Facial nerve in skullbase tumors: imaging and clinical relevance

Research

Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma

Research

The burden of critical illness among adults in a Swedish region—a population-based point-prevalence study

Research

Early administration of multiple vasopressors is associated with better survival in patients with sepsis: a propensity score-weighted study